India invests to boost domestic API manufacture

By Ben Hargreaves

- Last updated on GMT

(Image: Getty/Undefined undefined)
(Image: Getty/Undefined undefined)

Related tags India Coronavirus API

Following API constraints due to the coronavirus, the Indian government takes measures to bolster domestic capabilities.

The Indian government has set aside Rs. 10,000 crore ($1.2bn) for the pharmaceutical industry to shift the country away from its reliance on active pharmaceutical ingredients (APIs) produced in China.

Due to the emergence of the novel coronavirus, API production has been hampered in China, which had a knock-on impact for global supply.

As a result, the Indian government ordered the limit of the export of certain APIs and formulations​.

In attempt to prevent a similar occurrence in the future, the Indian government plans to finance the construction of three bulk drug parks, through an investment of Rs. 3,000 crore over the next five years.

In addition, the government will create a production-linked incentive scheme for the promotion of domestic manufacturing of critical drug intermediates and APIs in the country.

The Indian Pharmaceutical Alliance (IPA) welcomed the decision by calling it a “a major step in the creation of a self-sufficient healthcare ecosystem,”​ further suggesting that currently the industry is ‘dependent’ on China for many APIs and intermediates.

In a statement, Dilip Shanghvi, managing director of Sun Pharma, said the move would “safeguard healthcare security and create [an] ecosystem for [a] strong Indian API industry.”

According to Prashant Khadayate, pharma analyst at Global Data, the government has identified 53 APIs that it would like manufacturers to focus on.

Further than strengthening its domestic base, Khadayate stated that the action would “cement India’s position as a hub of API supply for the global markets in the future.”

At present, India contributes around 20% of the global generics market, with the country’s manufacturers representing approximately a third of the US market by volume.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us